The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07069725 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Fibrosis
Hepatic Cirrhosis

Interventions

DRUG: AZD2389
DIAGNOSTIC_TEST: PET scan and radioligand

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]